Universe and liquidity
Market cap, listing, free float, trading volumes and data availability. We exclude situations where spreads make trading execution fragile.
An approach combining quantitative screening, fundamental analysis, business valuation and risk assessment. We look for understandable, sustainable businesses, not simply stocks whose prices have risen.
A small-cap share represents ownership of a real business. To understand its potential, we analyze how it makes money, how much capital it needs, how it grows and which competitive advantages it may sustain over time.
Our starting point is to distinguish revenue expansion from value creation: a company may increase sales by 30% annually while burning cash, issuing new shares and reducing economic value per shareholder. That is why we assess revenue and margins together with invested capital, free cash flow, debt and dilution.
There is no universal valuation multiple. A cyclical industrial manufacturer, a recurring-revenue software company and a pre-revenue biotech require different metrics. Our main investment universe covers US and European companies below USD 5 billion, while exploratory screening can extend to USD 10 billion before applying a stricter filter.
“Price is what you pay; value is what you get.”Warren Buffett, a principle discussed in Berkshire Hathaway shareholder letters · Source
Practical example: consider two companies with identical revenue growth (+20%). The first improves its operating margin from 10% to 16% and generates cash. The second sees margins fall from 10% to 6% and funds losses through new equity issuance. The headline growth is identical; economic quality is not. Our methodology aims to measure precisely this distinction.
Market cap, listing, free float, trading volumes and data availability. We exclude situations where spreads make trading execution fragile.
Revenue, margins, returns on capital, free cash flow, net debt, maturities and outstanding share count.
Customers, pricing, contracts, competitors, market share, entry barriers and revenue concentration.
Incentives, dilution, acquisitions, guidance credibility, governance and execution capabilities.
Valuation through discounted cash flow or peer multiples, with conservative, base and optimistic scenarios and a margin of safety.
Quarterly results, revised assumptions, liquidity, catalysts and developments that might invalidate the original thesis.
Applied Digital illustrates how markets can rapidly revalue a company exposed to AI computing infrastructure. This is not a documented transaction from Davide's Portfolio.
Case sources: May 2025 monthly price history · October and November 2025 closing prices · Reuters, infrastructure agreement.
The following checklist is a proposed working methodology, not a certified record of rules already applied to Davide's Portfolio. It is designed to narrow the initial stock universe before qualitative review. Thresholds need to be tailored to each sector and are not sufficient grounds for buying.
| Category | Metric | Proposed initial threshold | How to interpret it |
|---|---|---|---|
| Universe | Market capitalization | USD 100m–10bn | Working preference: below USD 5bn; assess microcaps below USD 100m separately |
| Universe | Market and liquidity | US / Europe · average trading value ≥ USD 0.5m/day | Consider spreads, free float and exit capacity |
| Growth | 3-year revenue CAGR | ≥ 10% | Assess organic growth and the comparison base |
| Growth | Last-year revenue growth | ≥ 8% | Check order backlog, customer base and recurring revenue |
| Profitability | Gross margin | ≥ 30% for non-industrial models | Compare within sectors; not appropriate for all businesses |
| Profitability | EBITDA margin | ≥ 12% or improving trend | Do not directly compare companies following different accounting practices |
| Profitability | ROIC | ≥ 10% where meaningful | Prefer returns above the cost of capital |
| Cash | Free cash flow | Positive or credible path to positive within 24 months | Temporarily exempt R&D-intensive businesses from a strict filter |
| Cash | FCF / net income conversion | ≥ 70% if net income is positive | Check working capital and exceptional capital expenditures |
| Financial strength | Net debt / EBITDA | ≤ 2.5× with positive EBITDA | Carefully interpret leases and cyclical businesses |
| Financial strength | EBIT / interest coverage | ≥ 3× | If EBIT is negative, analyze remaining cash and debt maturities |
| Financial strength | Current ratio | ≥ 1,2× | For software and service businesses, cash runway also matters |
| Financial strength | Cash runway | ≥ 24 months for loss-making businesses | Calculate using normalized burn rate and funds actually available |
| Valuation | Forward EV / EBITDA | ≤ 15× where applicable | Not an automatic criterion for high-growth software |
| Valuation | EV / revenue | ≤ 4× as an indicative filter | Adjust for margins, growth, sector and recurring revenue |
| Valuation | Forward P/E | ≤ 25× with positive earnings | Use normalized earnings rather than an anomalous single year |
| Valuation | Discount to estimated fair value | ≥ 20–30% | Margin of safety depends on uncertainty |
| Quality | Annual share dilution | ≤ 3% under normal circumstances | Monitor stock-based compensation, warrants and convertibles |
| Quality | Customer concentration | Largest customer preferably < 25% of revenue | Warning threshold, not automatic exclusion |
| Catalysts | Events over the next 6–18 months | At least one identifiable catalyst | Contracts, margins, new products, debt reduction |
Definitions: CAGR = compound annual growth rate; FCF = operating cash flow minus capital expenditures; EV = enterprise value; ROIC = return on invested capital. Banks, insurers, financial companies and pre-revenue biotechs require specialized screening. Forward-looking data are estimates, not certain facts.
A screener identifies candidates, not certain opportunities. Before considering a business for a model portfolio, we need a written thesis, explicit assumptions, downside scenarios and monitoring criteria.
Can the business model be explained clearly? Where do cash flows come from?
What advantages protect margins, customer relationships and returns on capital?
Does the price provide a margin of safety appropriate to the downside scenarios?
What would change our view? Which signs of deterioration should be monitored?
“Growth is always a component in the calculation of value.”Warren Buffett, Berkshire Hathaway, 1992 shareholder letter · Original text
Warning: The methodology does not eliminate the risk of loss. These parameters are not personalized recommendations. Historical portfolio results require reporting supported by verifiable records and calculation methods.
Discover access plans and research on US and European businesses.
Editorial nature of the service. AlphaSmallCap publishes general research on US and European listed companies, educational materials and information on the author's portfolio. Content is intended for a general audience, including when made available through a subscription.
Davide's Portfolio. Viewing the portfolio's holdings and transactions serves informational and documentary purposes and is not an invitation to make similar trades. Descriptions of transactions as real, hypothetical or simulated must be consistent with the data and evidence presented on the respective pages.
No personalized advice. The service does not assess individual readers' investment objectives, assets or risk appetite, does not manage third-party assets and does not place orders on users' behalf. This explanation does not replace any obligations that may apply to general recommendations concerning financial instruments.
Investment risks and market information. Equity investments, particularly small caps, involve volatility, potentially limited liquidity, dilution risk and the possibility of losing the entire invested capital. Estimates, educational examples and past performance do not guarantee future returns.
Sources and interests. Data and valuations may be incomplete or change over time. Any relevant interests of the author, methodologies, sources and conflicts must be disclosed in research reports whenever required under applicable regulations.
Further information. See theRisk Disclosure, the research methodology, the Privacy Policy and the terms and conditions.